PHILADELPHIA, March 31: Morgan Lewis is pleased to announce that its Life Sciences and Healthcare practice ranked first in European Life Sciences Licensing Deals, leading other top firms in the year-end rankings for league tables compiled by BioPharm Insight.
Our Life Sciences and Healthcare group continues to place among the top firms for licensing activities in the life sciences industry and placed among premier firms in other categories as well based on both value and volume. In addition to leading in Europe, the firm placed second both globally and in the United States in terms of the value of the deals concluded over the last 12 months.
BioPharm Insight is a market provider of up-to-date information and coverage of global drug licensing deals as they take place. It publishes quarterly league tables to rank licensing activity in the life sciences industry, based on pharmaceutical drug licensing agreements announced during the period. In addition to the firm’s exceptional ranking in the latest tables, Morgan Lewis has received the following rankings from BioPharm Insight in the last 12 months:
2014 Fourth Quarter Only